Standard BioTools Inc (LAB) Shares Plummet Below 1-Year High

SNOW Stock

The stock of Standard BioTools Inc (NASDAQ: LAB) has decreased by -4.35 when compared to last closing price of 1.84. Despite this, the company has experienced a -0.56% fall in its stock price over the last five trading sessions. reported 2024-06-24 that We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

Is It Worth Investing in Standard BioTools Inc (NASDAQ: LAB) Right Now?

The 36-month beta value for LAB is at 1.67. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for LAB is 363.91M, and currently, shorts hold a 3.66% of that float. The average trading volume for LAB on July 11, 2024 was 3.20M shares.

LAB’s Market Performance

The stock of Standard BioTools Inc (LAB) has seen a -0.56% decrease in the past week, with a -24.14% drop in the past month, and a -39.73% fall in the past quarter. The volatility ratio for the week is 4.70%, and the volatility levels for the past 30 days are at 6.18% for LAB. The simple moving average for the past 20 days is -10.02% for LAB’s stock, with a -24.52% simple moving average for the past 200 days.

Analysts’ Opinion of LAB

Many brokerage firms have already submitted their reports for LAB stocks, with TD Cowen repeating the rating for LAB by listing it as a “Buy.” The predicted price for LAB in the upcoming period, according to TD Cowen is $3.50 based on the research report published on April 16, 2024 of the current year 2024.

Jefferies, on the other hand, stated in their research note that they expect to see LAB reach a price target of $3.25. The rating they have provided for LAB stocks is “Buy” according to the report published on April 04th, 2024.

KeyBanc Capital Markets gave a rating of “Overweight” to LAB, setting the target price at $4 in the report published on July 12th of the previous year.

LAB Trading at -22.89% from the 50-Day Moving Average

After a stumble in the market that brought LAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.30% of loss for the given period.

Volatility was left at 6.18%, however, over the last 30 days, the volatility rate increased by 4.70%, as shares sank -26.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.87% lower at present.

During the last 5 trading sessions, LAB fell by -0.56%, which changed the moving average for the period of 200-days by -35.53% in comparison to the 20-day moving average, which settled at $1.9235. In addition, Standard BioTools Inc saw -20.36% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at LAB starting from Casdin Partners Master Fund, L, who purchase 100,000 shares at the price of $2.60 back on May 23 ’24. After this action, Casdin Partners Master Fund, L now owns 46,075,821 shares of Standard BioTools Inc, valued at $260,000 using the latest closing price.

Casdin Partners Master Fund, L, the Director of Standard BioTools Inc, purchase 150,000 shares at $2.58 during a trade that took place back on May 22 ’24, which means that Casdin Partners Master Fund, L is holding 45,975,821 shares at $387,735 based on the most recent closing price.

Stock Fundamentals for LAB

Current profitability levels for the company are sitting at:

  • -0.73 for the present operating margin
  • 0.49 for the gross margin

The net margin for Standard BioTools Inc stands at -0.71. The total capital return value is set at -0.14. Equity return is now at value -37.47, with -15.66 for asset returns.

Based on Standard BioTools Inc (LAB), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -1.6. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -26.74.

Currently, EBITDA for the company is -47.86 million with net debt to EBITDA at 2.78. When we switch over and look at the enterprise to sales, we see a ratio of 3.6. The receivables turnover for the company is 3.52for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.50.


In conclusion, Standard BioTools Inc (LAB) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts